Drug maker Lupin on January 7 said that it has received approval from the US health regulator to market Lurasidone Hydrochloride tablets, used in the treatment of schizophrenia, in the American market.
The company said that it has received approval from the US Food and Drug Administration (FDA) to market its product, which is a generic version of Sunovion Pharmaceuticals Inc’s Latuda tablets, in strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, Lupin said in a regulatory filing.
The drug is indicated for conditions like schizophrenia and bipolar depression.
As per IQVIA MAT September 2018 data, Latuda Tablets had sales of around $3,217.3 million in the US market.
Lupin shares on Monday closed 1.03 per cent down at Rs 820.40 on the NSE.